Skip to Content

SWOG S0931: EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study

Objective
This study is being conducted to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning.
IRB Protocol Number
11-0545
Principal Investigator(s)
ELAINE LAM

Cancer Trials

  • Kidney Cancer
Sponsor(s)
SWOG
Contact
NICOLE CHRONISTER at 720-848-0602
or NICOLE.CHRONISTER@ucdenver.edu
Eligibility and Other Participant Information
What To Expect : A screening period will be conducted to determine eligibility. Treatment period can last up to 54 weeks. A follow up period will consist of clinic visits every six months for the first two years and then yearly thereafter until 10 years after registration. // Eligibility criteria include but are not limited to 18 years or older with cancer of the kidney.

Location

  • Shaw Regional Cancer Center (Vail)
  • ST. MARYS HOSPITAL - G.J.
  • Valley View Hospital